RBCC Targets Companion Diagnostics Opportunities in Booming $232 Billion
Personalized Medicine Market
NOKOMIS, Fla. -- April 08, 2013
As Rainbow Coral Corp.’s (OTCBB: RBCC) biotech subsidiary, Rainbow
BioSciences, seeks out potentially lucrative new opportunities in the $232
billion personalized medicine market, the company announced today that it will
target new innovations in the growing field of companion diagnostics.
The personalized medicine market in the U.S. is ripe for expansion, with
PricewaterhouseCoopers predicting that the sector could grow to as much as
$452 billion by 2015. One of the fastest-growing fields in the market is
companion diagnostics, which could grow to as large as $42 billion by 2015,
according to industry analysts TriMarkPublications.com.
The key to that growth will be innovation. Companion diagnostics is the use of
genetic variation to chart different patient responses to specific drugs or
biologic agents in order to create effective, efficient treatments tailored to
a patient’s genetic profile. The emerging field is believed by many medical
experts to have an increasingly important role to play in cancer treatments in
“Companion diagnostics represent the very cutting edge of technology in
medicine today,” said RBCC CEO Patrick Brown. “We believe the key to our
success is bringing desperately needed new innovations to the market that will
improve patient outcomes and reduce healthcare costs. Companion diagnostics
offer us the best opportunities to achieve that goal.”
For more information on Rainbow BioSciences’ personalized medicine
initiatives, please visitwww.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research technology
innovations to compete alongside companies such as Bristol Myers Squibb Co.
(NYSE:BMY),Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT)
and Amgen Inc. (NASDAQ:AMGN).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp.
(OTCBB:RBCC). The Company continually seeks out new partnerships with
biotechnology developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business initiatives,
please visitwww.RainbowBioSciences.com. For investment information and
performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This news release contains forward-looking information within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended, including statements
that include the words "believes," "expects," "anticipate" or similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results, performance
or achievements of the Company to differ materially from those expressed or
implied by such forward-looking statements. In addition, description of
anyone's past success, either financial or strategic, is no guarantee of
future success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information included
herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
Press spacebar to pause and continue. Press esc to stop.